share_log

Morgan Stanley Upgrades PTC Therapeutics to Equal-Weight, Raises Price Target to $30

Benzinga ·  Apr 29 05:11

Morgan Stanley analyst Jeffrey Hung upgrades PTC Therapeutics (NASDAQ:PTCT) from Underweight to Equal-Weight and raises the price target from $28 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment